CN111888466A - 一种改善仔猪腹泻的组合物及其制备方法 - Google Patents
一种改善仔猪腹泻的组合物及其制备方法 Download PDFInfo
- Publication number
- CN111888466A CN111888466A CN202010687129.XA CN202010687129A CN111888466A CN 111888466 A CN111888466 A CN 111888466A CN 202010687129 A CN202010687129 A CN 202010687129A CN 111888466 A CN111888466 A CN 111888466A
- Authority
- CN
- China
- Prior art keywords
- diarrhea
- composition
- piglets
- improving
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 150000004676 glycans Chemical class 0.000 claims abstract description 18
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 18
- 239000005017 polysaccharide Substances 0.000 claims abstract description 18
- 239000006041 probiotic Substances 0.000 claims abstract description 14
- 235000018291 probiotics Nutrition 0.000 claims abstract description 14
- 102000004190 Enzymes Human genes 0.000 claims abstract description 11
- 108090000790 Enzymes Proteins 0.000 claims abstract description 11
- 230000000529 probiotic effect Effects 0.000 claims abstract description 5
- 241000196324 Embryophyta Species 0.000 claims description 10
- 241000208340 Araliaceae Species 0.000 claims description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 8
- 235000008434 ginseng Nutrition 0.000 claims description 8
- 108090000145 Bacillolysin Proteins 0.000 claims description 5
- 102000035092 Neutral proteases Human genes 0.000 claims description 5
- 108091005507 Neutral proteases Proteins 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 229960002181 saccharomyces boulardii Drugs 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 230000036039 immunity Effects 0.000 abstract description 11
- 235000016709 nutrition Nutrition 0.000 abstract description 8
- 206010004016 Bacterial diarrhoea Diseases 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 2
- 206010016766 flatulence Diseases 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 25
- 230000000694 effects Effects 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 230000002354 daily effect Effects 0.000 description 14
- 230000003078 antioxidant effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000282887 Suidae Species 0.000 description 6
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 229940118019 malondialdehyde Drugs 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 235000014590 basal diet Nutrition 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000021050 feed intake Nutrition 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000021316 daily nutritional intake Nutrition 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000013777 protein digestion Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 208000026775 severe diarrhea Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000002792 antioxidant assay Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 239000006027 corn-soybean meal Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/189—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Gastroenterology & Hepatology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Physiology (AREA)
- Fodder In General (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种改善仔猪腹泻的组合物及其制备方法,包括按重量计的以下有效成分:植物多糖10‑30份;益生菌10‑30份;酶制剂5‑20份;组合物的制备方法为将植物多糖和酶制剂混合,控制湿度≤60%并加入益生菌混合,即得;该组合物针对21‑28日龄断奶仔猪应激引起的细菌性及营养性腹泻问题,改善仔猪腹泻、缓解母猪胀气,提升自身机体免疫与个体健康。
Description
技术领域
本发明涉及一种改善仔猪腹泻的组合物及其制备方法,属于动物饲养技术领域。
背景技术
在仔猪的饲养过程中,由于断奶应激引起的猪细菌性及营养性腹泻问题,普遍存在于猪场中。解决相关问题,一直以来以高剂量的氧化锌、硫酸铜以及抗生素等作为解决仔猪腹泻的关键技术。但是,随着饲料中锌离子、铜离子的限量使用及抗生素的禁用,对面临断奶应激、环境应激、日粮结构变化等综合应激下的断奶仔猪生产管理将造成巨大的影响。
现有技术中存在预防和治疗乳仔猪细菌性腹泻的微生态,其中涉及的有效成分如低聚木糖、嗜酸乳杆菌等成分在防控细菌性腹泻中具有一定效果,但同时发现,嗜酸乳杆菌普通粉制剂稳定性非常差,微囊包被型嗜酸乳杆菌成本过高,目前在养殖业中大范围使用难度较大。
还有一种功能类似的微粒制剂,主要是通过微囊包被定点释放技术,使黄酮类物质可以经过胃部直接在肠道释放,从而提高黄酮类物质在口服使用后的生物利用率;该系统的抗腹泻效果主要来源于黄酮类活性成分的“类鸦片”效果,即减缓动物胃肠道蠕动,调整通过肠粘膜的电解质流。
发明内容
为了克服现有技术的不足,本发明的第一个目的在于提供一种改善仔猪腹泻的组合物,该组合物针对21-28日龄断奶仔猪应激引起的细菌性及营养性腹泻问题,改善仔猪腹泻、缓解母猪胀气,提升自身机体免疫与个体健康。
本发明的第二个目的在于提供一种上述改善仔猪腹泻的组合物的制备方法。
实现本发明的第一个目的可以通过采取如下技术方案达到:一种改善仔猪腹泻的组合物,包括按重量计的以下有效成分:
植物多糖 10-30份;
益生菌 10-30份;
酶制剂 5-20份。
进一步地,包括按重量计的以下有效成分:
植物多糖 20份;
益生菌 20份;
酶制剂 10份。
进一步地,植物多糖为人参多糖。
进一步地,人参多糖为以人参叶经粉碎、水煮、二次醇沉、减压干燥、粉碎而得。
进一步地,益生菌为布拉迪酵母。
进一步地,益生菌含酵母活菌数≥200亿个/g。
进一步地,酶制剂为中性蛋白酶。
进一步地,中性蛋白酶含量20000U/g。
进一步地,改善仔猪腹泻的组合物还包括载体,重量份50-65份。
进一步地,载体包括麸皮和药渣中的至少一种。
实现本发明的第二个目的可以通过采取如下技术方案达到:一种改善仔猪腹泻的组合物的制备方法,将植物多糖和酶制剂混合,控制湿度≤60%并加入益生菌混合,即得。
相比现有技术,本发明的有益效果在于:
1、本发明改善仔猪腹泻的组合物以植物多糖、益生菌和酶制剂进行搭配组合,植物多糖具有促进营养物质的消化、吸收,改善营养性腹泻的功能;同时,多糖中的小分子糖又是后肠有益微生物的养分来源,与益生菌协同,可促进肠道固有菌群的生长繁殖,协助动物体建立专属的菌群平衡,提升自身机体免疫与个体健康,增强疾病入侵时的抵抗力;
2、本发明改善仔猪腹泻的组合物使用简单方法,成分天然无副作用,适用于畜类饲养;
3、本发明改善仔猪腹泻的组合物的制备方法简单高效,适合批量生产。
附图说明
图1为实施例2对仔猪腹泻改善的效果比较;
图2实施例1-3对断奶仔猪血清抗氧化指标GSH-PX的影响;
图3实施例1-3对断奶仔猪血清抗氧化指标SOD的影响;
图4实施例1-3对断奶仔猪血清抗氧化指标MDA的影响。
具体实施方式
下面,结合附图以及具体实施方式,对本发明做进一步描述:
一种改善仔猪腹泻的组合物,包括按重量计的以下有效成分:
其中,人参多糖为以人参叶经粉碎、水煮、二次醇沉、减压干燥、粉碎而得。人参多糖中含有多种单糖,包括甘露糖、葡萄糖醛酸、鼠李糖、半乳糖醛酸、葡萄糖、半乳糖、木糖、阿拉伯糖等,人参叶多糖是天然的益生元复合体,在改善机体免疫能力的同时可促进肠道固有菌群增殖,维持菌群平衡是天然的益生元复合体,在改善机体免疫能力的同时可促进肠道固有菌群增殖,维持菌群平衡。
其中,布拉迪酵母活菌数≥200亿个/g。
其中,中性蛋白酶含量20000U/g。
布拉迪酵母具有抑制毒素与肠上皮刷状缘上受体结合,从而降低梭菌肠毒素和细胞毒性的作用,在动物肠道活化后可分泌抗毒素物质,直接降解病原菌产生的毒素,并通过促进肠道黏膜屏障修复来增强黏膜免疫及抗炎功能;仔猪断奶后高蛋白、高系酸力日粮的摄入与尚未成熟的消化酶分泌系统的矛盾,导致仔猪出现普遍的营养性腹泻与消化不良问题,考虑防控细菌性腹泻的基础上增加了辅助提高仔猪蛋白消化率的外源性蛋白酶,减少由于蛋白消化不充分而引起的营养性腹泻问题。
实施例1-3:
改善仔猪腹泻的组合物,实施例1-3包括按表格1所示以重量计的有效成分:
表格1实施例1-3的成分及用量
试验例1:
对实施例1-3进行效果的试验:
(一)试验设计
本试验采用单因素随机分组试验设计。选取160头体重相近的28日龄断奶仔猪,统一转入保育舍,随机分为4组,分别为空白对照组、实施例1-3组,每组5个重复,每个重复8头猪。除空白对照组外,其他组分别在基础日粮中按照2kg/t添加实施例1-3。。试验全期仔猪自由饮水,并按照试验场管理制度执行定期免疫程序。试验期为5周。
1、试验日粮
基础日粮为玉米-豆粕型,参照NRC(2012)标准配制,无抗生素和药物。基础饲粮组成及营养水平如表格2所示。
表格2基础饲粮组成及营养水平(风干基础)
注:每公斤预混料提供:维生素A:12000IU;维生素D3:2500IU;维生素E:15mg;维生素K3:3.0mg;维生素B1:1.5mg;维生素B2:7.0mg;维生素B6:2.0mg;维生素B12:0.025mg;生物素:0.2mg;叶酸:0.85mg;烟酸:50mg;泛酸:25mg;铁:100mg;铜:50mg;锰:60mg;锌:150mg;碘:0.75mg;硒:0.36mg。
2、饲养管理
试验在温氏食品集团股份有限公司试验猪场进行,整个试验期间严格按照猪场规定,统一进行驱虫。试验猪每天饲喂3次,保证每次以采食后料槽有少许余料为标准,确保所有猪仔自由采食和饮水。保持猪舍清洁卫生和空气流通,定期对猪圈进行清扫和消毒。
3、样品采集
于试验开始前称取断奶仔猪个体重,于试验期第2周和第5周早晨对仔猪进行称重(采样前一天晚上断料),并每天对每组仔猪料槽中剩料进行收集称重,记录耗料量。记录试验仔猪每天的腹泻情况,计算腹泻率。
4、检测指标与方法
(1)生长性能
记录每周的投料量以及剩余量。试验结束后计算全期的平均采食量、平均体重、平均日增重以及饲料转化率并进行统计分析。
平均采食量=平均日投料量-平均日剩料量
平均日增重=(末重-初重)/仔猪总数×天数
料肉比=平均采食量/平均日增重
(2)腹泻率
观察并记录每天仔猪腹泻头数,待试验结束计算出腹泻率。
腹泻频次(%)=腹泻头日数总头数/(猪头数×试验天数)×100%
其中:腹泻头日数指每天仔猪发生腹泻的头数,即有1头仔猪发生腹泻,则为1个头日数。
5、数据处理
用Excel软件对数据进行初步的整理,用SPSS 19.0软件进行数据分析和统计,各指标用One-way ANOVA进行显著性分析,用LSD法进行多重比较,结果采用平均数±标准差表示,p<0.05为差异显著性标准。
(二)实施例1-3对断奶仔猪生产性能的影响
实施例1-3对断奶仔猪生产性能的影响如表格3所示。
表格3实施例1-3对断奶仔猪生产性能的影响
由表格3可知,与对照组相比,试验0-2周时,实施例1-3的体重分别显著(p<0.05)增加了9.10%、10.73%和10.83%;平均日增重分别提高了21.41%、28.72%、28.82%,差异均达极显著水平(p<0.01);料肉比分别降低了11.18%、18.42%、18.42%,差异均达极显著水平(p<0.01),腹泻率分别降低了63.28%、73.76%和70.75%,差异均达极显著水平(p<0.01)。而实施例1-3之间各项指标差异均不显著(p>0.05)。实施例1-3组和对照组相比平均日采食量有所提高(p>0.05)。
试验0-5周结果显示,相较于对照组,实施例1-3的体重分别显著(p<0.05)增加了11.98%、13.43%、10.93%;平均日采食量分别显著(p<0.05)增加了11.85%、12.35%、9.79%;平均日增重分别显著增加了17.97%(p<0.05)、20.13%(p<0.01)、16.47%(p<0.01);料肉比分别显著(p<0.05)降低了5.66%、6.29%、5.66%。实施例1-3的腹泻率比对照组的分别极显著(p<0.01)降低46.71%、51.91%和48.38%。
以上结果表明实施例1-3可显著提高了仔猪的平均体重、平均日采食量、平均日增重以及显著降低料重比和腹泻率。
试验例2:
实施例2对断奶仔猪腹泻的效果试验:
(一)试验目的
本试验旨在评估本发明实施例2在大生产环境中防控仔猪腹泻的效果。
(二)试验动物
23日龄三元(杜×长×大)断奶仔猪294头,温氏阳春养猪分公司种猪场提供。
(三)试验方法
选择日龄相近(不超过2天)、健康的断奶仔猪294头,随机分成2个处理,每处理7重复,每重复21头仔猪。对照组饲喂基础日粮,试验组基础日粮中按照2kg/t饲喂,周期为14天,试验期间试验猪分餐饲喂,自由饮水,其它按猪场日常管理程序进行。
(四)测定项目
每天记录仔猪腹泻情况,腹泻程度分“轻度”、“中度”和“重度”腹泻三种类型。其中,“轻度”:软粪便,半成形;“中度”:较稀,不成形;“重度”:水样。
腹泻率=腹泻总头次×100%/(试验总头数×试验总天数)。
(五)结果分析与讨论
实施例2对仔猪腹泻的改善如图1所示。从图1得知,仔猪断奶后2周内,添加2kg/t实施例2腹泻率比对照组降低了7.94%,其中重度腹泻率占比降低了2.1%,中度腹泻率占比降低了11.13%。
仔猪断奶后,由于长途运输、日粮转变、环境变化等应激影响,肠道功能出现紊乱,机体免疫力下降,严重者表现出不同程度的腹泻现象。实施例2含有多种单糖,如甘露糖、葡萄糖醛酸等,它能提高机体抗氧化、非特异性免疫能力等功能,辅助提升防治腹泻能力。
(六)结论
大生产中,在饲料中添加2kg/t实施例2可有效降低断奶仔猪2周内的腹泻率,且减少了“中度”和“重度”腹泻率占比,维护肠道健康,改善饲料消化吸收率。
试验例3:
研究实施例1-3抗腹泻机理研究:
(一)试验设计与饲养管理同试验例1。
(二)样品采集
于试验第5周清晨,每个重复组随机选取2头仔猪(空腹),前腔静脉采血10mL血置于未加抗凝剂的管中,4℃放置30min后,4000rpm,离心10min,分离血清,分装3份,-20℃保存,待测定血清免疫以及抗氧化活性指标。
(三)检测指标与方法
1、血清免疫球蛋白的测定
采用ELISA试剂盒测定免疫球蛋白(IgA、IgG、IgM)的浓度,样品严格按试剂盒的操作说明书进行检测。
2、血清抗氧化测定
血清中的总超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)、和丙二醛(MDA)含量均采用南京建成生物工程所研制的试剂盒检测,测定过程均严格按照试剂盒说明书的步骤进行操作。
(四)数据处理
用Excel软件对数据进行初步的整理,用SPSS 19.0软件进行数据分析和统计,各指标用One-way ANOVA进行显著性分析,用LSD法进行多重比较,结果采用平均数±标准差表示,p<0.05为差异显著性标准。
(五)结果与分析
1、实施例1-3对断奶仔猪抗氧化活性的影响
实施例1-3对断奶仔猪血清抗氧化指标影响如图2-4所示。与对照组相比,实施例2和3组可增加断奶仔猪血清中GSH-Px(p<0.05)和SOD活性(p<0.01),降低断奶仔猪血清中MDA浓度(p<0.05)。说明实施例2和3可增加机体抗氧化能力,抑制脂质过氧化,从而改善动物机体健康状况,提高断奶仔猪的生长性能。
2、实施例1-3对断奶仔猪免疫功能的影响
研究结果如表格4所示,在仔猪日粮中添加2kg/t的实施例2和3均极显著(p<0.01)提高了断奶仔猪血清中IgG、IgM和IgA浓度。而添加实施例3效果最好,但与添加实施例2相比,血清中IgG和IgA浓度差异不显著(p>0.05),但血清中IgM浓度差异显著(p<0.05)。综上所述,饲料中添加实施例2和3可不同程度的提高断奶仔猪血清中IgG、IgM和IgA含量,增强断奶仔猪机体免疫力,从而提高断奶仔猪生长性能。
表格4对断奶仔猪免疫功能的影响
综上,本发明具有显著的促进断奶仔猪生长和防腹泻的作用。其作用机制体现为:增强断奶仔猪血清中GSH-Px、SOD等抗氧化酶活性,降低血清中脂质过氧化产物MDA含量,从而减轻和阻止活性氧的过氧化作用,提高机体抗氧化能力,增强机体免疫功能,最终达到促生长和防腹泻的作用,是可代替抗生素的绿色添加剂。
对于本领域的技术人员来说,可根据以上描述的技术方案以及构思,做出其它各种相应的改变以及变形,而所有的这些改变以及变形都应该属于本发明权利要求的保护范围之内。
Claims (10)
1.一种改善仔猪腹泻的组合物,其特征在于包括按重量计的以下有效成分:
植物多糖10-30份;
益生菌10-30份;
酶制剂5-20份。
2.如权利要求1所述的改善仔猪腹泻的组合物,其特征在于包括按重量计的以下有效成分:
植物多糖20份;
益生菌20份;
酶制剂10份。
3.如权利要求1所述的改善仔猪腹泻的组合物,其特征在于,所述植物多糖为人参多糖。
4.如权利要求3所述的改善仔猪腹泻的组合物,其特征在于,所述人参多糖为以人参叶经粉碎、水煮、二次醇沉、减压干燥、粉碎而得。
5.如权利要求1所述的改善仔猪腹泻的组合物,其特征在于,所述益生菌为布拉迪酵母。
6.如权利要求5所述的改善仔猪腹泻的组合物,其特征在于,所述益生菌含酵母活菌数≥200亿个/g。
7.如权利要求1所述的改善仔猪腹泻的组合物,其特征在于,所述酶制剂为中性蛋白酶。
8.如权利要求7所述的改善仔猪腹泻的组合物,其特征在于,所述中性蛋白酶含量20000U/g。
9.如权利要求1所述的改善仔猪腹泻的组合物,其特征在于,所述改善仔猪腹泻的组合物还包括载体,重量份50-65份。
10.一种改善仔猪腹泻的组合物的制备方法,其特征在于,将植物多糖和酶制剂混合,控制湿度≤60%并加入益生菌混合,即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010687129.XA CN111888466A (zh) | 2020-07-16 | 2020-07-16 | 一种改善仔猪腹泻的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010687129.XA CN111888466A (zh) | 2020-07-16 | 2020-07-16 | 一种改善仔猪腹泻的组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111888466A true CN111888466A (zh) | 2020-11-06 |
Family
ID=73191045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010687129.XA Pending CN111888466A (zh) | 2020-07-16 | 2020-07-16 | 一种改善仔猪腹泻的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111888466A (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005073553A (ja) * | 2003-08-29 | 2005-03-24 | Daicho Kikaku:Kk | 動物飼料添加剤及び動物飼料 |
KR20090115393A (ko) * | 2008-05-02 | 2009-11-05 | 한정만 | 인삼의 잎과 줄기추출물을 이용한 양돈용 사료첨가제 |
CN102178060A (zh) * | 2011-05-13 | 2011-09-14 | 湖北邦之德牧业科技有限公司 | 替代饲料中血浆蛋白的生物多肽 |
CN103238727A (zh) * | 2013-05-29 | 2013-08-14 | 河南牧鹤(集团)饲料有限公司 | 一种膨化小麦型保育猪饲料及其制备方法 |
CN104127443A (zh) * | 2014-07-25 | 2014-11-05 | 吉林省农业科学院 | 一种乳酸菌与人参多糖组合物及其制备方法与应用 |
CN105267957A (zh) * | 2015-10-30 | 2016-01-27 | 北京昕大洋科技发展有限公司 | 一种猪用生物止泻剂及其制备方法和应用 |
CN106889328A (zh) * | 2017-02-22 | 2017-06-27 | 湖南九鼎科技(集团)有限公司 | 保育猪用无抗生素饲料及其制备方法 |
CN108210586A (zh) * | 2018-01-04 | 2018-06-29 | 中国农业大学 | 一种用于缓解断奶仔猪腹泻、改善其肠道健康的纯天然植物成分添加剂 |
CN110250355A (zh) * | 2019-07-04 | 2019-09-20 | 山东畜牧兽医职业学院 | 一种保育猪预防腹泻的小料及其饲料 |
-
2020
- 2020-07-16 CN CN202010687129.XA patent/CN111888466A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005073553A (ja) * | 2003-08-29 | 2005-03-24 | Daicho Kikaku:Kk | 動物飼料添加剤及び動物飼料 |
KR20090115393A (ko) * | 2008-05-02 | 2009-11-05 | 한정만 | 인삼의 잎과 줄기추출물을 이용한 양돈용 사료첨가제 |
CN102178060A (zh) * | 2011-05-13 | 2011-09-14 | 湖北邦之德牧业科技有限公司 | 替代饲料中血浆蛋白的生物多肽 |
CN103238727A (zh) * | 2013-05-29 | 2013-08-14 | 河南牧鹤(集团)饲料有限公司 | 一种膨化小麦型保育猪饲料及其制备方法 |
CN104127443A (zh) * | 2014-07-25 | 2014-11-05 | 吉林省农业科学院 | 一种乳酸菌与人参多糖组合物及其制备方法与应用 |
CN105267957A (zh) * | 2015-10-30 | 2016-01-27 | 北京昕大洋科技发展有限公司 | 一种猪用生物止泻剂及其制备方法和应用 |
CN106889328A (zh) * | 2017-02-22 | 2017-06-27 | 湖南九鼎科技(集团)有限公司 | 保育猪用无抗生素饲料及其制备方法 |
CN108210586A (zh) * | 2018-01-04 | 2018-06-29 | 中国农业大学 | 一种用于缓解断奶仔猪腹泻、改善其肠道健康的纯天然植物成分添加剂 |
CN110250355A (zh) * | 2019-07-04 | 2019-09-20 | 山东畜牧兽医职业学院 | 一种保育猪预防腹泻的小料及其饲料 |
Non-Patent Citations (2)
Title |
---|
C.M.YANG等: "Astragalus and Ginseng Polysaccharides Improve Developmental,Intestinal Morphological,and Immune Functional Characters of Weaned Piglets" * |
刘祝英: "复合多糖对断奶仔猪生产性能和免疫功能影响的研究" * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Effects of adding essential oil to the diet of weaned pigs on performance, nutrient utilization, immune response and intestinal health | |
CN106819481B (zh) | 一种用于仔猪教槽的全价发酵饲料及其制备方法 | |
CN102232467B (zh) | 畜禽抗腹泻饲料添加剂及其制备方法 | |
CN110604226A (zh) | 断奶仔猪用防腹泻促生长复合饲料添加剂及其制备方法 | |
CN103652476A (zh) | 肉鸭饲料 | |
CN113812528A (zh) | 一种改善畜禽肠道健康的植物提取物添加剂 | |
CN105581045A (zh) | 一种改善仔猪肠道健康的饲料添加剂及其制备方法 | |
Li et al. | Effects of dietary supplementation with Clostridium butyricum on the amelioration of growth performance, rumen fermentation, and rumen microbiota of holstein heifers | |
CN111513177A (zh) | 一种中草药发酵饲料的制备方法 | |
CN110892944A (zh) | 一种可替代抗生素的断奶仔猪饲料添加剂及其应用 | |
CN114568602A (zh) | 一种提高肉鸡生长性能和机体免疫的中药复方及其制备方法和应用 | |
CN109480111A (zh) | 一种增强免疫力的猪饲料添加剂及其应用 | |
CN103815143B (zh) | 一种能提高牲畜非特异性免疫功能的牲畜饲料添加剂 | |
CN112167458A (zh) | 一种魔芋飞粉在母猪饲料中的应用及母猪饲料 | |
CN102754733A (zh) | 一种新型猪用微生态制剂及其制备方法 | |
CN111888466A (zh) | 一种改善仔猪腹泻的组合物及其制备方法 | |
KR102197664B1 (ko) | 항균 또는 항바이러스제 조성물과 그 제조방법 및 제품 | |
CN114304413A (zh) | 一种含酸化剂的复合物及其制备方法 | |
KR102105829B1 (ko) | 열용융압출법을 이용하여 제조된 산화아연 나노콜로이드 분산체 및 이의 용도 | |
CN112021459A (zh) | 一种改善仔猪应激的饲料添加剂 | |
CN108184767B (zh) | 一种养牛的方法 | |
CN112704164A (zh) | 一种益生菌肉鸡饲料及其制备方法 | |
CN106417918A (zh) | 畜禽用含硒、em益生菌添加剂及其应用 | |
Lei et al. | Growth performance, nutrient digestibility, and selected fecal microbiota are improved by β-glucan supplementation in weaner pigs | |
Artawiguna et al. | Administration of Fermented Soursop (Annona Muricata) Leaf Water Extract Through Drinking Water on the Performance of Joper Male Chickens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201106 |
|
RJ01 | Rejection of invention patent application after publication |